Wedbush Reiterates $34.00 Price Target for Aquestive Therapeutics (AQST)

Share on StockTwits

Wedbush set a $34.00 target price on Aquestive Therapeutics (NASDAQ:AQST) in a research note released on Wednesday. The brokerage currently has a buy rating on the stock.

AQST has been the topic of a number of other reports. JMP Securities started coverage on shares of Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating and a $29.00 price target on the stock. Royal Bank of Canada started coverage on shares of Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating and a $23.00 price target on the stock. Finally, BMO Capital Markets started coverage on shares of Aquestive Therapeutics in a research report on Monday, August 20th. They set an outperform rating on the stock.

Shares of AQST stock opened at $14.90 on Wednesday. The company has a debt-to-equity ratio of -1.16, a current ratio of 1.14 and a quick ratio of 0.95. Aquestive Therapeutics has a fifty-two week low of $13.61 and a fifty-two week high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, September 4th. The company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.66). The business had revenue of $13.93 million for the quarter. Sell-side analysts forecast that Aquestive Therapeutics will post -0.93 earnings per share for the current fiscal year.

In other Aquestive Therapeutics news, Director Douglas K. Bratton purchased 165,000 shares of Aquestive Therapeutics stock in a transaction on Tuesday, July 24th. The shares were purchased at an average cost of $15.00 per share, with a total value of $2,475,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Further Reading: Average Daily Trade Volume Explained

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply